[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGjF5L33zSdp5zg9_fjfy5wZV0WhhX3RsuKMUCVZSZbo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Centre Hospitalier Universitaire de Besancon",[4],443,false,71,21,810744,28,351,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Breast Cancer",15,{"name":18,"count":19},"Depression",9,{"name":21,"count":22},"Cirrhosis",8,{"name":24,"count":25},"Cancer",6,{"name":27,"count":25},"Metastatic Colorectal Cancer",{"name":29,"count":25},"Disorder Related to Renal Transplantation",{"name":31,"count":32},"Colorectal Cancer",4,{"name":34,"count":32},"Lung Cancer",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02839291","Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life","2024-02-05","intravenous or oral bone antiresorptive treatments",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04719988","Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","2024-11-21","Blood sample collection",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04894370","Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma","2025-06-01","Sample collection",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05664815","Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management","2025-09","Human Amniotic Membrane",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06327308","Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.","2025-09-01","Blood sampling",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05168839","Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage","2025-10-31","FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06744400","Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk","2026-01-20","Grafalon® administered during 5 consecutive days at 2 mg\u002Fkg\u002Fj",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07067099","Neutralizing Interferon Type 1 in Hidradenitis Suppurativa","2026-06","Plasma with neutralizing autoantibodies to Type I Interferons",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05824442","Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis","2026-10","Blood sample for multiplex QPCR technique",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05241561","Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients","2027-03","Cabozantinib",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,152,221,244,270,290,308,326,391,413,440,462,488,511,529,547,569,595,613,635,739,763,781,799,819,841,862,888,910,935,962,980,1007,1025,1043,1068,1095,1113,1160,1182,1217,1239,1276,1301,1328,1346,1372,1398,1423,1450,1478,1496,1514,1532,1557,1575,1593,1619,1646,1664,1682,1705,1745,1776,1798,1824,1848,1866,1892,1910,1928,1946,1973,1998,2024,2042,2060,2086,2104,2128,2154,2180,2198,2225,2243,2268,2297,2315,2339,2357,2375,2393,2411,2434,2459,2485,2503,2521,2539,2557,2581,2607,2633,2660,2683,2705,2732,2758,2782,2808,2833,2860,2878,2903,2929,2954,2981,3007],{"intervention":95,"totalTrials":96,"cells":97},"Regorafenib",3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":133,"PHASE4":148,"NA":150},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":132,"soonestReadout":110},[105,117],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT06425133","Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","RECRUITING",[89],"2027-09","2028-09","2024-07-19",174,[27],[95,116],"Regorafenib + metronomic chemotherapy",{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":128},"NCT04534218","Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","COMPLETED",[89],"2023-12-13","2020-10-16",49,[126,127],"Colo-rectal Cancer","Metastatic Cancer",[95,129,130,131],"Cyclophosphamide","Capecitabine","Aspirin",1,{"trials":134,"activeCount":132,"soonestReadout":139},[135],{"nctId":136,"briefTitle":137,"status":108,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":144},"NCT05462613","Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer",[89,90],"2029-11","2030-11","2023-05-09",446,[27],[95,145,131,146,147],"Metronomic chemotherapies","Bevacizumab","FOLFIRI or FOLFOX",{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":100},[],{"intervention":146,"totalTrials":153,"cells":154},5,{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":199,"PHASE4":205,"NA":207},{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":132,"soonestReadout":175},[161,171,184],{"nctId":162,"briefTitle":163,"status":120,"phases":164,"primaryCompletion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT02821559","Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer",[89],"2014-08","2012-07",37,[27],[170,146],"TOMOX",{"nctId":172,"briefTitle":173,"status":108,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT05528952","Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma",[89],"2028-03-27","2030-02-27","2022-09-27",105,[180],"Hepatocellular Carcinoma",[182,146,183],"Atezolizumab","UCPVax",{"nctId":185,"briefTitle":186,"status":187,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT03117972","Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","TERMINATED",[89],"2024-08-07","2024-11-18","2017-08-04",54,[27],[195,196,197,146,198,130],"FOLFOXIRI","FOLFOX","FOLFIRI","LV5FU2",{"trials":200,"activeCount":132,"soonestReadout":139},[201],{"nctId":136,"briefTitle":137,"status":108,"phases":202,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":203,"interventions":204},[89,90],[27],[95,145,131,146,147],{"trials":206,"activeCount":100},[],{"trials":208,"activeCount":100},[209],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT02842294","Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer","UNKNOWN",[],"2017-02","2018-02","2013-05",320,[27,219],"Quality of Life",[146],{"intervention":131,"totalTrials":222,"cells":223},2,{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":234,"PHASE4":240,"NA":242},{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"trials":229,"activeCount":100},[230],{"nctId":118,"briefTitle":119,"status":120,"phases":231,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":232,"interventions":233},[89],[126,127],[95,129,130,131],{"trials":235,"activeCount":132,"soonestReadout":139},[236],{"nctId":136,"briefTitle":137,"status":108,"phases":237,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":238,"interventions":239},[89,90],[27],[95,145,131,146,147],{"trials":241,"activeCount":100},[],{"trials":243,"activeCount":100},[],{"intervention":245,"totalTrials":132,"cells":246},"prednisone - oral corticosteroid 1mg\u002Fkg\u002FD for 1 week",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":266,"NA":268},{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[],{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":132,"soonestReadout":260},[255],{"nctId":256,"briefTitle":257,"status":258,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT07067801","Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss.","NOT_YET_RECRUITING",[90],"2028-12","2025-11",430,[264],"Sudden Sensorineural Hearing Loss",[245],{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"intervention":65,"totalTrials":132,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":286,"NA":288},{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":100},[],{"trials":277,"activeCount":100},[],{"trials":279,"activeCount":132,"soonestReadout":64},[280],{"nctId":62,"briefTitle":63,"status":108,"phases":281,"primaryCompletion":64,"completion":64,"start":282,"enrollment":283,"conditions":284,"interventions":285},[90],"2022-09-26",1010,[31],[65],{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":100},[],{"intervention":145,"totalTrials":132,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":304,"NA":306},{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":132,"soonestReadout":139},[300],{"nctId":136,"briefTitle":137,"status":108,"phases":301,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":302,"interventions":303},[89,90],[27],[95,145,131,146,147],{"trials":305,"activeCount":100},[],{"trials":307,"activeCount":100},[],{"intervention":147,"totalTrials":132,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":322,"NA":324},{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":132,"soonestReadout":139},[318],{"nctId":136,"briefTitle":137,"status":108,"phases":319,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":320,"interventions":321},[89,90],[27],[95,145,131,146,147],{"trials":323,"activeCount":100},[],{"trials":325,"activeCount":100},[],{"intervention":183,"totalTrials":153,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":329,"activeCount":100},[],{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":222,"soonestReadout":175},[334,346,359,369,381],{"nctId":335,"briefTitle":336,"status":120,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT04280848","Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma",[89],"2023-12-21","2024-12-31","2020-05-26",67,[343],"Glioblastoma",[183,345],"Temozolomide",{"nctId":347,"briefTitle":348,"status":120,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":358},"NCT03946358","Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)",[89],"2024-03-01","2024-11-01","2020-02-18",47,[355,356,357],"Squamous Cell Carcinoma of the Head and Neck","Anal Canal Cancer","Cervical Cancer",[45,182,183],{"nctId":360,"briefTitle":361,"status":120,"phases":362,"primaryCompletion":363,"completion":339,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT02818426","Universal Cancer Peptide-based Vaccination in Metastatic NSCLC",[88,89],"2022-08-30","2016-04-20",82,[367],"Metastatic Non-small Cell Lung Cancer",[183],{"nctId":370,"briefTitle":371,"status":258,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT07347210","Evaluation of UCPVax Vaccine +\u002F- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma",[89],"2029-01","2029-07","2026-01",98,[378],"Primary Glioblastoma",[183,380,345],"Pembrolizumab",{"nctId":172,"briefTitle":173,"status":108,"phases":382,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":383,"interventions":384},[89],[180],[182,146,183],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"intervention":345,"totalTrials":222,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"trials":398,"activeCount":132,"soonestReadout":373},[399,403],{"nctId":335,"briefTitle":336,"status":120,"phases":400,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":401,"interventions":402},[89],[343],[183,345],{"nctId":370,"briefTitle":371,"status":258,"phases":404,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":405,"interventions":406},[89],[378],[183,380,345],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[],{"intervention":45,"totalTrials":222,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":416,"activeCount":100},[],{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":132,"soonestReadout":44},[421,430],{"nctId":42,"briefTitle":43,"status":422,"phases":423,"primaryCompletion":44,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},"ACTIVE_NOT_RECRUITING",[89],"2026-07-05","2022-01-04",55,[428],"Squamous Cell Carcinoma of the Anus Stage III",[45],{"nctId":347,"briefTitle":348,"status":120,"phases":431,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":432,"interventions":433},[89],[355,356,357],[45,182,183],{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"intervention":182,"totalTrials":222,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":443,"activeCount":100},[],{"trials":445,"activeCount":100},[],{"trials":447,"activeCount":132,"soonestReadout":175},[448,452],{"nctId":347,"briefTitle":348,"status":120,"phases":449,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":450,"interventions":451},[89],[355,356,357],[45,182,183],{"nctId":172,"briefTitle":173,"status":108,"phases":453,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":454,"interventions":455},[89],[180],[182,146,183],{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"intervention":463,"totalTrials":132,"cells":464},"Carboplatin",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":466,"activeCount":100},[],{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":132,"soonestReadout":475},[471],{"nctId":472,"briefTitle":473,"status":108,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":192,"conditions":478,"interventions":481},"NCT02735057","Chemoradiotherapy in Elderly Patients With Oesophagus Cancer",[88,89],"2028-11-16","2029-05-16","2016-04-04",[479,480],"Oesophagus Cancer","Elderly Patients",[463],{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"intervention":50,"totalTrials":132,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":132,"soonestReadout":49},[496],{"nctId":47,"briefTitle":48,"status":108,"phases":497,"primaryCompletion":49,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":504},[89],"2026-11-01","2022-06-09",34,[502,503],"Squamous Cell Anal Carcinoma","Metastatic Squamous Cell Carcinoma",[50],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":100},[],{"intervention":116,"totalTrials":132,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":514,"activeCount":100},[],{"trials":516,"activeCount":100},[],{"trials":518,"activeCount":132,"soonestReadout":110},[519],{"nctId":106,"briefTitle":107,"status":108,"phases":520,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":521,"interventions":522},[89],[27],[95,116],{"trials":524,"activeCount":100},[],{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"intervention":380,"totalTrials":132,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":100},[],{"trials":536,"activeCount":132,"soonestReadout":373},[537],{"nctId":370,"briefTitle":371,"status":258,"phases":538,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":539,"interventions":540},[89],[378],[183,380,345],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"intervention":55,"totalTrials":132,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":132,"soonestReadout":54},[555],{"nctId":52,"briefTitle":53,"status":108,"phases":556,"primaryCompletion":54,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},[89],"2026-03","2023-09-22",66,[561],"Osteonecrosis Due to Drugs, Jaw",[55],{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":100},[],{"trials":568,"activeCount":100},[],{"intervention":570,"totalTrials":132,"cells":571},"MP0317 + Gemcitabine + Cisplatine + Durvalumab",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":132,"soonestReadout":582},[578],{"nctId":579,"briefTitle":580,"status":108,"phases":581,"primaryCompletion":582,"completion":139,"start":583,"enrollment":584,"conditions":585,"interventions":587},"NCT07036380","MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma",[89],"2028-11","2025-12-22",75,[586],"Advanced Biliary Tract Carcinoma",[570,588],"Gemcitabine + Cisplatin + Durvalumab",{"trials":590,"activeCount":100},[],{"trials":592,"activeCount":100},[],{"trials":594,"activeCount":100},[],{"intervention":588,"totalTrials":132,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":598,"activeCount":100},[],{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":132,"soonestReadout":582},[603],{"nctId":579,"briefTitle":580,"status":108,"phases":604,"primaryCompletion":582,"completion":139,"start":583,"enrollment":584,"conditions":605,"interventions":606},[89],[586],[570,588],{"trials":608,"activeCount":100},[],{"trials":610,"activeCount":100},[],{"trials":612,"activeCount":100},[],{"intervention":85,"totalTrials":132,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":132,"soonestReadout":84},[621],{"nctId":82,"briefTitle":83,"status":258,"phases":622,"primaryCompletion":84,"completion":84,"start":623,"enrollment":624,"conditions":625,"interventions":627},[89],"2022-06",24,[626],"Cancer of Kidney",[85,628],"Blood sample",{"trials":630,"activeCount":100},[],{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"intervention":628,"totalTrials":19,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":647,"PHASE4":649,"NA":661},{"trials":638,"activeCount":100},[],{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":132,"soonestReadout":84},[643],{"nctId":82,"briefTitle":83,"status":258,"phases":644,"primaryCompletion":84,"completion":84,"start":623,"enrollment":624,"conditions":645,"interventions":646},[89],[626],[85,628],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[651],{"nctId":652,"briefTitle":653,"status":120,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT02862314","PROcalcitonin Pneumonia \u002F Pneumonitis Associated With ASPIration",[91],"2019-11-28","2015-02-24",167,[659],"Inhalation Pneumonia",[628],{"trials":662,"activeCount":100},[663,674,685,696,706,717,728],{"nctId":664,"briefTitle":665,"status":120,"phases":666,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT02116270","Accelerated Immunosenescence and Chronic Kidney Disease",[92],"2016-08","2017-01","2013-09",222,[672],"Renal Failure",[628],{"nctId":675,"briefTitle":676,"status":212,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":426,"conditions":681,"interventions":683},"NCT02862301","Epigenetic Evaluation of HAT\u002FHDAC Activity in PBMC From Patients With Clinically Isolated Syndrome",[92],"2020-06","2020-09","2016-04",[682],"Demyelinating Autoimmune Diseases, CNS",[684],"blood sample",{"nctId":686,"briefTitle":687,"status":187,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT02375711","Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient",[92],"2016-09","2017-09","2014-03",20,[694],"Chronic Renal Disease",[628],{"nctId":697,"briefTitle":698,"status":120,"phases":699,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT02839278","Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases",[92],"2024-09-02","2015-04",150,[704],"Inflammation",[628],{"nctId":707,"briefTitle":708,"status":120,"phases":709,"primaryCompletion":710,"completion":711,"start":712,"conditions":713,"interventions":716},"NCT01487850","Wind Instruments' Fungal Contamination",[92],"2007-06","2007-10","2007-05",[714,715],"Immunologically-induced Lung Disease","Hypersensitivity Pneumonitis",[684],{"nctId":718,"briefTitle":719,"status":212,"phases":720,"primaryCompletion":557,"completion":557,"start":721,"enrollment":722,"conditions":723,"interventions":727},"NCT05704218","Hypersensitivity Pneumonitis of Domestic Origin",[92],"2023-02",500,[724,725,726],"Sensitisation","Mold or Dust Allergy","Respiratory Disease",[684],{"nctId":729,"briefTitle":730,"status":212,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":737},"NCT05138666","Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.",[92],"2024-03","2022-09-16",363,[736],"Invasive Pulmonary Aspergillosis",[738,684],"respiratory sample",{"intervention":70,"totalTrials":132,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":132,"soonestReadout":69},[745],{"nctId":67,"briefTitle":68,"status":258,"phases":746,"primaryCompletion":69,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":752},[88],"2027-01-15","2025-01-15",18,[751],"Renal Transplantation",[70,753,754],"Grafalon® administered during 5 consecutive days at 1 mg\u002Fkg\u002Fj","Grafalon® administered during 5 consecutive days at 0,5 mg\u002Fkg\u002Fj",{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"trials":762,"activeCount":100},[],{"intervention":753,"totalTrials":132,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":132,"soonestReadout":69},[769],{"nctId":67,"briefTitle":68,"status":258,"phases":770,"primaryCompletion":69,"completion":747,"start":748,"enrollment":749,"conditions":771,"interventions":772},[88],[751],[70,753,754],{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":100},[],{"intervention":754,"totalTrials":132,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":791,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":132,"soonestReadout":69},[787],{"nctId":67,"briefTitle":68,"status":258,"phases":788,"primaryCompletion":69,"completion":747,"start":748,"enrollment":749,"conditions":789,"interventions":790},[88],[751],[70,753,754],{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"intervention":75,"totalTrials":132,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":132,"soonestReadout":74},[805],{"nctId":72,"briefTitle":73,"status":258,"phases":806,"primaryCompletion":74,"completion":807,"start":54,"enrollment":25,"conditions":808,"interventions":810},[88],"2026-09",[809],"Hidradenitis Suppurativa (HS)",[75],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"trials":816,"activeCount":100},[],{"trials":818,"activeCount":100},[],{"intervention":80,"totalTrials":132,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":132,"soonestReadout":79},[833],{"nctId":77,"briefTitle":78,"status":108,"phases":834,"primaryCompletion":79,"completion":79,"start":835,"enrollment":836,"conditions":837,"interventions":840},[92],"2023-10-24",43,[838,839],"Echinococcosis","Diagnosis",[80],{"intervention":60,"totalTrials":132,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":132,"soonestReadout":59},[855],{"nctId":57,"briefTitle":58,"status":258,"phases":856,"primaryCompletion":59,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":861},[],"2027-06-01","2024-09-01",60,[21],[60],{"intervention":863,"totalTrials":132,"cells":864},"Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":866,"activeCount":100},[],{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":132,"soonestReadout":881},[877],{"nctId":878,"briefTitle":879,"status":258,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT07392788","Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department",[92],"2027-12","2028-02","2026-04",144,[886],"Acute Heart Failure (AHF)",[863],{"intervention":40,"totalTrials":132,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":132,"soonestReadout":39},[902],{"nctId":37,"briefTitle":38,"status":422,"phases":903,"primaryCompletion":39,"completion":904,"start":905,"enrollment":906,"conditions":907,"interventions":909},[92],"2025-01-31","2016-06-14",148,[908],"Tumor With Bone Metastasis",[40],{"intervention":911,"totalTrials":132,"cells":912},"Tocilizumab",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":921,"NA":933},{"trials":914,"activeCount":100},[],{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":100},[923],{"nctId":924,"briefTitle":925,"status":120,"phases":926,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":932},"NCT02843789","Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy",[91],"2017-11","2013-03",109,[931],"Arthritis, Rheumatoid",[911],{"trials":934,"activeCount":100},[],{"intervention":936,"totalTrials":132,"cells":937},"Cefotaxime",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":960},{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[948],{"nctId":949,"briefTitle":950,"status":212,"phases":951,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT03922919","Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)",[91],"2020-04-03","2020-10","2018-04-03",250,[957],"Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)",[936,959],"Cefotaxime\u002Fceftriaxone",{"trials":961,"activeCount":100},[],{"intervention":959,"totalTrials":132,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":970,"PHASE4":972,"NA":978},{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[974],{"nctId":949,"briefTitle":950,"status":212,"phases":975,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":976,"interventions":977},[91],[957],[936,959],{"trials":979,"activeCount":100},[],{"intervention":981,"totalTrials":132,"cells":982},"Indacaterol",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":991,"NA":1005},{"trials":984,"activeCount":100},[],{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[993],{"nctId":994,"briefTitle":995,"status":120,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1002},"NCT02872090","Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)",[91],"2021-06-01","2016-03",42,[1001],"Chronic Obstructive Pulmonary Disease",[981,1003,1004],"Glycopyrronium","Tiotropium",{"trials":1006,"activeCount":100},[],{"intervention":1003,"totalTrials":132,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1023},{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"trials":1018,"activeCount":100},[1019],{"nctId":994,"briefTitle":995,"status":120,"phases":1020,"primaryCompletion":997,"completion":997,"start":998,"enrollment":999,"conditions":1021,"interventions":1022},[91],[1001],[981,1003,1004],{"trials":1024,"activeCount":100},[],{"intervention":1004,"totalTrials":132,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1041},{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[1037],{"nctId":994,"briefTitle":995,"status":120,"phases":1038,"primaryCompletion":997,"completion":997,"start":998,"enrollment":999,"conditions":1039,"interventions":1040},[91],[1001],[981,1003,1004],{"trials":1042,"activeCount":100},[],{"intervention":1044,"totalTrials":132,"cells":1045},"Fampridine",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1054,"NA":1066},{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[1056],{"nctId":1057,"briefTitle":1058,"status":120,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT02849782","Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.",[91],"2019-03-01","2014-02-04",89,[1064],"Multiple Sclerosis",[1044],{"trials":1067,"activeCount":100},[],{"intervention":1069,"totalTrials":132,"cells":1070},"Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1093},{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":100},[],{"trials":1076,"activeCount":100},[],{"trials":1078,"activeCount":100},[],{"trials":1080,"activeCount":100},[1081],{"nctId":1082,"briefTitle":1083,"status":120,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT01559753","Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment",[91],"2002-09","2002-11","1998-01",225,[1090],"Pneumonia Ventilator Associated",[1069,1092],"compare 8 to15 days of antibiotic treatment",{"trials":1094,"activeCount":100},[],{"intervention":1092,"totalTrials":132,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":100},[1107],{"nctId":1082,"briefTitle":1083,"status":120,"phases":1108,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1109,"interventions":1110},[91],[1090],[1069,1092],{"trials":1112,"activeCount":100},[],{"intervention":1114,"totalTrials":222,"cells":1115},"Intravenous dexamethasone",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1156,"NA":1158},{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[1124,1140],{"nctId":1125,"briefTitle":1126,"status":120,"phases":1127,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1137},"NCT03688269","Minimal Effective Concentration (EC90) of Ropivacaine",[90],"2019-11-04","2020-05-04","2018-10-05",146,[1133,1134,1135,1136],"Anesthesia, Conduction","Ropivacaine","Dexamethasone","Axillary Brachial Plexus Block",[1114,1138,1139],"Intravenous saline","Perineural ropivacaine",{"nctId":1141,"briefTitle":1142,"status":120,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1152},"NCT02862327","Intravenous Dexamethasone for Ropivacaine Axillary Block",[90],"2017-03-16","2017-09-16","2016-12-01",99,[1149,1150,1151],"Postoperative Pain","Anesthesia","Forearm Injuries",[1153,1154,1155],"intravenous dexamethasone","intravenous placebo","perineural ropivacaine",{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[],{"intervention":1139,"totalTrials":222,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1178,"NA":1180},{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":100},[1170,1174],{"nctId":1125,"briefTitle":1126,"status":120,"phases":1171,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":1131,"conditions":1172,"interventions":1173},[90],[1133,1134,1135,1136],[1114,1138,1139],{"nctId":1141,"briefTitle":1142,"status":120,"phases":1175,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1176,"interventions":1177},[90],[1149,1150,1151],[1153,1154,1155],{"trials":1179,"activeCount":100},[],{"trials":1181,"activeCount":100},[],{"intervention":1183,"totalTrials":222,"cells":1184},"Exenatide",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1213,"NA":1215},{"trials":1186,"activeCount":100},[],{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[1193,1205],{"nctId":1194,"briefTitle":1195,"status":120,"phases":1196,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":1200,"conditions":1201,"interventions":1203},"NCT01969149","Exenatide for Stress Hyperglycemia",[89,90],"2015-12","2016-12","2015-01",110,[1202],"Stress Hyperglycemia",[1183,1204],"Insulin",{"nctId":1206,"briefTitle":1207,"status":120,"phases":1208,"primaryCompletion":668,"completion":668,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT02432976","Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients",[89,90],"2015-05",64,[219],[1183,1204],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"intervention":1204,"totalTrials":222,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1235,"NA":1237},{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[1227,1231],{"nctId":1194,"briefTitle":1195,"status":120,"phases":1228,"primaryCompletion":1197,"completion":1198,"start":1199,"enrollment":1200,"conditions":1229,"interventions":1230},[89,90],[1202],[1183,1204],{"nctId":1206,"briefTitle":1207,"status":120,"phases":1232,"primaryCompletion":668,"completion":668,"start":1209,"enrollment":1210,"conditions":1233,"interventions":1234},[89,90],[219],[1183,1204],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[],{"intervention":1240,"totalTrials":222,"cells":1241},"Modulation of Inspired Fraction of Oxygen",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1272,"NA":1274},{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[1250,1262],{"nctId":1251,"briefTitle":1252,"status":212,"phases":1253,"primaryCompletion":1254,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1261},"NCT02713451","Liberal Oxygenation Versus Conservative Oxygenation in ARDS",[90],"2019-05-31","2019-09-28","2016-06",206,[1259,1260],"Acute Respiratory Distress Syndrome","Intensive Care",[1240],{"nctId":1263,"briefTitle":1264,"status":212,"phases":1265,"primaryCompletion":1266,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1271},"NCT03621293","Long Term Outcome on Brain and Lung of Different Oxygen Strategies in ARDS Patients",[90],"2021-03-20","2021-09-20","2017-09-20",259,[1259],[1240],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"intervention":1277,"totalTrials":132,"cells":1278},"Remifentanil",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1297,"NA":1299},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[1287],{"nctId":1288,"briefTitle":1289,"status":120,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1296},"NCT02093143","Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia",[90],"2013-02","2009-06",256,[1295],"Tumor of Ear, Nose and Throat",[1277],{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"intervention":1302,"totalTrials":132,"cells":1303},"PCA with Chlorhydrate of Morphine",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1324,"NA":1326},{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[1312],{"nctId":1313,"briefTitle":1314,"status":212,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1199,"enrollment":859,"conditions":1318,"interventions":1322},"NCT02292667","Efficacy of the Ultrasound-guided Transversus Abdominis Plane Block in Open Aortic Abdominal Aneurysm Repair Surgery",[90],"2018-12","2019-01",[1319,1320,1321],"Aortic Aneurysm, Abdominal","Pain","Anesthesia, Local",[1302,1323],"Acetaminophen",{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"intervention":1323,"totalTrials":132,"cells":1329},{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1342,"NA":1344},{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[1338],{"nctId":1313,"briefTitle":1314,"status":212,"phases":1339,"primaryCompletion":1316,"completion":1317,"start":1199,"enrollment":859,"conditions":1340,"interventions":1341},[90],[1319,1320,1321],[1302,1323],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"intervention":1347,"totalTrials":132,"cells":1348},"Oxygen gas",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1368,"NA":1370},{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[1357],{"nctId":1358,"briefTitle":1359,"status":120,"phases":1360,"primaryCompletion":1361,"completion":1362,"start":1363,"enrollment":859,"conditions":1364,"interventions":1367},"NCT04990349","Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock",[90],"2023-11-10","2023-12-01","2022-01-09",[1365,1366],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation",[1347],{"trials":1369,"activeCount":100},[],{"trials":1371,"activeCount":100},[],{"intervention":1373,"totalTrials":132,"cells":1374},"Human Albumin",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1394,"NA":1396},{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[1383],{"nctId":1384,"briefTitle":1385,"status":187,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1393},"NCT01359813","Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis",[90],"2011-09","2012-06","2008-12",193,[21,1392,672],"Sepsis",[1373],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"intervention":1399,"totalTrials":132,"cells":1400},"Capsaicin patch",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1419,"NA":1421},{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[1409],{"nctId":1410,"briefTitle":1411,"status":187,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT02854670","A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia",[89,90],"2021-02-03","2016-01-20",10,[1417],"Vestibulodynia",[1399],{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[],{"intervention":1424,"totalTrials":132,"cells":1425},"Rifaximin",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1446,"NA":1448},{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":100},[1434],{"nctId":1435,"briefTitle":1436,"status":120,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1445},"NCT03069131","Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites",[90],"2022-06-03","2023-03-20","2018-06-05",160,[21,1443,1444],"Ascites","Peritonitis",[1424],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"intervention":1451,"totalTrials":132,"cells":1452},"Sodium Lactate",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1459,"PHASE4":1474,"NA":1476},{"trials":1454,"activeCount":100},[],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[1461],{"nctId":1462,"briefTitle":1463,"status":120,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1472},"NCT04488874","Sodium Lactate and Brain Relaxation (LSD)",[90],"2023-05-31","2023-06-30","2020-09-29",50,[1451,1470,1471],"Intracranial Hypertension","Brain Relaxation",[1451,1473],"Mannitol 20%",{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"intervention":1473,"totalTrials":132,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[1488],{"nctId":1462,"briefTitle":1463,"status":120,"phases":1489,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1490,"interventions":1491},[90],[1451,1470,1471],[1451,1473],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"intervention":1138,"totalTrials":132,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1504,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[1506],{"nctId":1125,"briefTitle":1126,"status":120,"phases":1507,"primaryCompletion":1128,"completion":1129,"start":1130,"enrollment":1131,"conditions":1508,"interventions":1509},[90],[1133,1134,1135,1136],[1114,1138,1139],{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"intervention":1154,"totalTrials":132,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[],{"trials":1523,"activeCount":100},[1524],{"nctId":1141,"briefTitle":1142,"status":120,"phases":1525,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1526,"interventions":1527},[90],[1149,1150,1151],[1153,1154,1155],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":1533,"totalTrials":132,"cells":1534},"Letrozole",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1553,"NA":1555},{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[1543],{"nctId":1544,"briefTitle":1545,"status":187,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":376,"conditions":1549,"interventions":1550},"NCT02730091","A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",[90],"2020-03-23","2016-02-24",[15],[1533,1551,1552],"Anastrozole","Vinorelbine",{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[],{"intervention":1551,"totalTrials":132,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1571,"NA":1573},{"trials":1560,"activeCount":100},[],{"trials":1562,"activeCount":100},[],{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":100},[1567],{"nctId":1544,"briefTitle":1545,"status":187,"phases":1568,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":376,"conditions":1569,"interventions":1570},[90],[15],[1533,1551,1552],{"trials":1572,"activeCount":100},[],{"trials":1574,"activeCount":100},[],{"intervention":1552,"totalTrials":132,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1589,"NA":1591},{"trials":1578,"activeCount":100},[],{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":100},[],{"trials":1584,"activeCount":100},[1585],{"nctId":1544,"briefTitle":1545,"status":187,"phases":1586,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":376,"conditions":1587,"interventions":1588},[90],[15],[1533,1551,1552],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[],{"intervention":1594,"totalTrials":132,"cells":1595},"Vildagliptin",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1615,"NA":1617},{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[1604],{"nctId":1605,"briefTitle":1606,"status":212,"phases":1607,"primaryCompletion":1608,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1614},"NCT02849899","Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period",[90],"2024-07","2024-12","2018-10-26",186,[29,1613],"Diabetes",[1594],{"trials":1616,"activeCount":100},[],{"trials":1618,"activeCount":100},[],{"intervention":1620,"totalTrials":132,"cells":1621},"MEROPENEM",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1642,"NA":1644},{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[1630],{"nctId":1631,"briefTitle":1632,"status":120,"phases":1633,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1639},"NCT02820987","PK\u002FPD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock",[90],"2018-10-04","2016-09-27",119,[1638],"Septic Shock",[1620,1640,1641],"PIPERACILLIN-TAZOBACTAM","CEFEPIME",{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[],{"intervention":1640,"totalTrials":132,"cells":1647},{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1654,"PHASE4":1660,"NA":1662},{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[1656],{"nctId":1631,"briefTitle":1632,"status":120,"phases":1657,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":1636,"conditions":1658,"interventions":1659},[90],[1638],[1620,1640,1641],{"trials":1661,"activeCount":100},[],{"trials":1663,"activeCount":100},[],{"intervention":1641,"totalTrials":132,"cells":1665},{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1678,"NA":1680},{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[1674],{"nctId":1631,"briefTitle":1632,"status":120,"phases":1675,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":1636,"conditions":1676,"interventions":1677},[90],[1638],[1620,1640,1641],{"trials":1679,"activeCount":100},[],{"trials":1681,"activeCount":100},[],{"intervention":1683,"totalTrials":132,"cells":1684},"Botulinum Toxin Type A",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1701,"NA":1703},{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"trials":1690,"activeCount":100},[],{"trials":1692,"activeCount":100},[1693],{"nctId":1694,"briefTitle":1695,"status":120,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":859,"conditions":1699,"interventions":1700},"NCT02858219","A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia",[90],"2019-02-11","2010-05-04",[1417],[1683],{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[],{"intervention":1706,"totalTrials":222,"cells":1707},"Cisplatin",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1709,"activeCount":100},[],{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[1714,1728],{"nctId":1715,"briefTitle":1716,"status":187,"phases":1717,"primaryCompletion":701,"completion":1718,"start":1719,"enrollment":1720,"conditions":1721,"interventions":1725},"NCT01830270","Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer",[89],"2016-07","2011-05",30,[1722,1723,1724],"Stomach Neoplasms","Oesophageal Junction Cancer","Lower Oesophagus Cancer",[1726,1706,1727],"Epirubicin","Paclitaxel",{"nctId":1729,"briefTitle":1730,"status":120,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":1734,"conditions":1735,"interventions":1737},"NCT02879227","Radiochemotherapy in Elderly Patients With Oesophagus Cancer",[89],"2014-12","2010-01",23,[1736],"Esophagus Cancer",[1706,1738],"Oxaliplatin",{"trials":1740,"activeCount":100},[],{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":100},[],{"intervention":129,"totalTrials":222,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1764,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1748,"activeCount":100},[],{"trials":1750,"activeCount":100},[1751],{"nctId":1752,"briefTitle":1753,"status":120,"phases":1754,"primaryCompletion":1755,"start":1756,"enrollment":19,"conditions":1757,"interventions":1759},"NCT02845999","Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab",[88],"2013-01","2009-11",[1758],"Gastrointestinal Metastatic Cancer",[1760,1761,129,1762,1763],"allogenic immunotherapy based on Natural Killer cells adoptive transfer","cetuximab","fludarabine","interleukin-2",{"trials":1765,"activeCount":100},[1766],{"nctId":118,"briefTitle":119,"status":120,"phases":1767,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":1768,"interventions":1769},[89],[126,127],[95,129,130,131],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":100},[],{"intervention":130,"totalTrials":222,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"trials":1783,"activeCount":100},[1784,1788],{"nctId":185,"briefTitle":186,"status":187,"phases":1785,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":1786,"interventions":1787},[89],[27],[195,196,197,146,198,130],{"nctId":118,"briefTitle":119,"status":120,"phases":1789,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":1790,"interventions":1791},[89],[126,127],[95,129,130,131],{"trials":1793,"activeCount":100},[],{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":100},[],{"intervention":1799,"totalTrials":132,"cells":1800},"Sunitinib",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[1807],{"nctId":1808,"briefTitle":1809,"status":212,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":1813,"conditions":1814,"interventions":1817},"NCT02689167","Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma",[89],"2024-02","2016-02-19",226,[1815,1816],"Kidney Neoplasms","Metastatic Renal Cell Cancer",[1799],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[],{"intervention":1825,"totalTrials":132,"cells":1826},"Estramustine",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":1836,"phases":1837,"primaryCompletion":1838,"completion":1838,"start":668,"enrollment":100,"conditions":1839,"interventions":1840},"NCT02853071","Efficacy and Safety of Estracyt® in Metastatic Breast Cancer","WITHDRAWN",[89],"2020-01",[15],[1825,1841],"standard practice",{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"intervention":1841,"totalTrials":132,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[1856],{"nctId":1834,"briefTitle":1835,"status":1836,"phases":1857,"primaryCompletion":1838,"completion":1838,"start":668,"enrollment":100,"conditions":1858,"interventions":1859},[89],[15],[1825,1841],{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[],{"intervention":1867,"totalTrials":132,"cells":1868},"UCPVax + Nivolumab",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"trials":1874,"activeCount":100},[1875],{"nctId":1876,"briefTitle":1877,"status":120,"phases":1878,"primaryCompletion":1879,"completion":1880,"start":1881,"enrollment":859,"conditions":1882,"interventions":1884},"NCT04263051","Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer",[89],"2023-11-22","2024-11-28","2020-09-09",[1883],"Advanced Non-small Cell Lung Cancer",[1867,1885],"standard chemotherapy",{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"intervention":1885,"totalTrials":132,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[1900],{"nctId":1876,"briefTitle":1877,"status":120,"phases":1901,"primaryCompletion":1879,"completion":1880,"start":1881,"enrollment":859,"conditions":1902,"interventions":1903},[89],[1883],[1867,1885],{"trials":1905,"activeCount":100},[],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"intervention":1726,"totalTrials":132,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[1918],{"nctId":1715,"briefTitle":1716,"status":187,"phases":1919,"primaryCompletion":701,"completion":1718,"start":1719,"enrollment":1720,"conditions":1920,"interventions":1921},[89],[1722,1723,1724],[1726,1706,1727],{"trials":1923,"activeCount":100},[],{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[],{"intervention":1727,"totalTrials":132,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":100},[1936],{"nctId":1715,"briefTitle":1716,"status":187,"phases":1937,"primaryCompletion":701,"completion":1718,"start":1719,"enrollment":1720,"conditions":1938,"interventions":1939},[89],[1722,1723,1724],[1726,1706,1727],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":100},[],{"intervention":1947,"totalTrials":132,"cells":1948},"Avelumab",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1967,"PHASE4":1969,"NA":1971},{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[1955],{"nctId":1956,"briefTitle":1957,"status":212,"phases":1958,"primaryCompletion":1959,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1966},"NCT03774901","Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma",[89],"2024-09-22","2019-03-12",32,[1963,1964,1965],"Penile Cancer","Penile Neoplasms","Penile Squamous Cell Carcinoma",[1947],{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":100},[],{"intervention":1974,"totalTrials":132,"cells":1975},"methotrexate",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1992,"PHASE4":1994,"NA":1996},{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[1982],{"nctId":1983,"briefTitle":1984,"status":120,"phases":1985,"primaryCompletion":1986,"completion":1987,"start":1988,"enrollment":1200,"conditions":1989,"interventions":1991},"NCT00498589","Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis",[89],"2014-02","2014-06","2007-09",[1990],"Ulcerative Colitis",[1974],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"intervention":1999,"totalTrials":132,"cells":2000},"Chemotherapy",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[2007],{"nctId":2008,"briefTitle":2009,"status":212,"phases":2010,"primaryCompletion":2011,"completion":2012,"start":2013,"enrollment":2014,"conditions":2015,"interventions":2017},"NCT03599960","Combination Chemotherapy in Patients With Newly Diagnosed BPDCN",[89],"2023-02-13","2024-11","2019-05-02",26,[2016],"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[1999],{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"intervention":1738,"totalTrials":132,"cells":2025},{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2036,"PHASE4":2038,"NA":2040},{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[2032],{"nctId":1729,"briefTitle":1730,"status":120,"phases":2033,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":1734,"conditions":2034,"interventions":2035},[89],[1736],[1706,1738],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"intervention":170,"totalTrials":132,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2054,"PHASE4":2056,"NA":2058},{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[2050],{"nctId":162,"briefTitle":163,"status":120,"phases":2051,"primaryCompletion":165,"start":166,"enrollment":167,"conditions":2052,"interventions":2053},[89],[27],[170,146],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[],{"intervention":2061,"totalTrials":132,"cells":2062},"T lymphocytes iCASP9 ΔCD19",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[2069],{"nctId":2070,"briefTitle":2071,"status":187,"phases":2072,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":222,"conditions":2075,"interventions":2078},"NCT02849886","T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.",[88,89],"2021-12-26","2019-04-10",[2076,2077],"Graft Versus Host Disease","Hematological Malignancies",[2061,2079],"Dimerizer drug AP1903",{"trials":2081,"activeCount":100},[],{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"intervention":2079,"totalTrials":132,"cells":2087},{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[2094],{"nctId":2070,"briefTitle":2071,"status":187,"phases":2095,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":222,"conditions":2096,"interventions":2097},[88,89],[2076,2077],[2061,2079],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"intervention":2105,"totalTrials":132,"cells":2106},"Autologous apoptotic cells",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2108,"activeCount":100},[],{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[2113],{"nctId":2114,"briefTitle":2115,"status":212,"phases":2116,"primaryCompletion":2117,"completion":1609,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2121},"NCT02903212","Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis",[88,89],"2024-06","2023-03",22,[931],[2105],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"intervention":2129,"totalTrials":132,"cells":2130},"Docetaxel, Cisplatin and 5-Fluorouracil",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2132,"activeCount":100},[],{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[2137],{"nctId":2138,"briefTitle":2139,"status":120,"phases":2140,"primaryCompletion":2141,"completion":2142,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2147},"NCT02402842","Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma",[89],"2018-06","2020-06-30","2014-09",70,[2146],"Anal Canal Carcinoma",[2129],{"trials":2149,"activeCount":100},[],{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":100},[],{"intervention":2155,"totalTrials":132,"cells":2156},"Metronomic cyclophosphamide",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2174,"PHASE4":2176,"NA":2178},{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[2163],{"nctId":2164,"briefTitle":2165,"status":120,"phases":2166,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":11,"conditions":2170,"interventions":2172},"NCT02838342","Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors",[89],"2020-04","2021-06-29","2015-05-19",[2171],"Neuroendocrine Tumors",[2155,2173],"Interferon-alpha",{"trials":2175,"activeCount":100},[],{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"intervention":2173,"totalTrials":132,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2183,"activeCount":100},[],{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[2188],{"nctId":2164,"briefTitle":2165,"status":120,"phases":2189,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":11,"conditions":2190,"interventions":2191},[89],[2171],[2155,2173],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"intervention":2199,"totalTrials":132,"cells":2200},"XELOXIRI-3",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[],{"trials":2206,"activeCount":100},[2207],{"nctId":2208,"briefTitle":2209,"status":187,"phases":2210,"primaryCompletion":2211,"completion":2212,"start":2213,"enrollment":2214,"conditions":2215,"interventions":2217},"NCT03974854","Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma",[89],"2023-08-01","2024-02-01","2019-07-08",25,[2216],"Metastatic Pancreatic Adenocarcinoma",[2199,2218],"Gemcitabine",{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[],{"intervention":2218,"totalTrials":132,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[2233],{"nctId":2208,"briefTitle":2209,"status":187,"phases":2234,"primaryCompletion":2211,"completion":2212,"start":2213,"enrollment":2214,"conditions":2235,"interventions":2236},[89],[2216],[2199,2218],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"intervention":2244,"totalTrials":132,"cells":2245},"nasal oxytocin or placebo",{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2247,"activeCount":100},[],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[2252],{"nctId":2253,"briefTitle":2254,"status":120,"phases":2255,"primaryCompletion":2256,"completion":2256,"start":2257,"enrollment":2258,"conditions":2259,"interventions":2261},"NCT02847143","Ocytocine and Cerebral Activation in Relation With Attachement",[89],"2018-04-27","2015-04-09",100,[2260],"Attachement Style",[2244],{"trials":2263,"activeCount":100},[],{"trials":2265,"activeCount":100},[],{"trials":2267,"activeCount":100},[],{"intervention":2269,"totalTrials":132,"cells":2270},"probiotic Vivomixx®",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[2277],{"nctId":2278,"briefTitle":2279,"status":212,"phases":2280,"primaryCompletion":2281,"completion":2282,"start":2283,"enrollment":2284,"conditions":2285,"interventions":2289},"NCT04769687","Symbiotics and Systemic Inflammation in Chronic Kidney Disease",[89],"2023-05-01","2023-11-01","2020-11-21",62,[2286,2287,2288],"Chronic Renal Failure","Diabete Type 2","Systemic Inflammation",[2269,2290],"prebiotic Orafti®Synergy1",{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"intervention":2290,"totalTrials":132,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2309,"PHASE4":2311,"NA":2313},{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[2305],{"nctId":2278,"briefTitle":2279,"status":212,"phases":2306,"primaryCompletion":2281,"completion":2282,"start":2283,"enrollment":2284,"conditions":2307,"interventions":2308},[89],[2286,2287,2288],[2269,2290],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[],{"trials":2314,"activeCount":100},[],{"intervention":2316,"totalTrials":132,"cells":2317},"Omalizumab",{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":100},[2324],{"nctId":2325,"briefTitle":2326,"status":120,"phases":2327,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":1415,"conditions":2330,"interventions":2332},"NCT02262130","Omalizumab in Severe and Refractory Solar Urticaria",[89],"2015-09-29","2014-09-30",[2331],"Solar Urticaria",[2316],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"intervention":195,"totalTrials":132,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[2347],{"nctId":185,"briefTitle":186,"status":187,"phases":2348,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":2349,"interventions":2350},[89],[27],[195,196,197,146,198,130],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"intervention":196,"totalTrials":132,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[2365],{"nctId":185,"briefTitle":186,"status":187,"phases":2366,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":2367,"interventions":2368},[89],[27],[195,196,197,146,198,130],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[],{"intervention":197,"totalTrials":132,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[2383],{"nctId":185,"briefTitle":186,"status":187,"phases":2384,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":2385,"interventions":2386},[89],[27],[195,196,197,146,198,130],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":100},[],{"trials":2392,"activeCount":100},[],{"intervention":198,"totalTrials":132,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2396,"activeCount":100},[],{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[2401],{"nctId":185,"briefTitle":186,"status":187,"phases":2402,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":2403,"interventions":2404},[89],[27],[195,196,197,146,198,130],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":100},[],{"trials":2410,"activeCount":100},[],{"intervention":2412,"totalTrials":132,"cells":2413},"Intravenous immunoglobulins",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[],{"trials":2419,"activeCount":100},[2420],{"nctId":2421,"briefTitle":2422,"status":120,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2425,"enrollment":1415,"conditions":2426,"interventions":2427},"NCT01360658","Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria",[89],"2013-06","2011-06",[2331],[2412],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[],{"intervention":2435,"totalTrials":132,"cells":2436},"Fosfomycin Oral Suspension",{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2453,"PHASE4":2455,"NA":2457},{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2444,"briefTitle":2445,"status":212,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2214,"conditions":2450,"interventions":2452},"NCT03868969","Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)",[89],"2021-04","2021-09","2019-04",[2451],"Urinary Tract Infections",[2435],{"trials":2454,"activeCount":100},[],{"trials":2456,"activeCount":100},[],{"trials":2458,"activeCount":100},[],{"intervention":2460,"totalTrials":132,"cells":2461},"Oxytocin",{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[2466],{"nctId":2467,"briefTitle":2468,"status":120,"phases":2469,"primaryCompletion":2470,"completion":2470,"start":2471,"enrollment":2472,"conditions":2473,"interventions":2476},"NCT02301715","Effects of Intranasal Oxytocin on Emotion Regulation in Adolescents",[88],"2017-05-31","2014-04-29",29,[2474,2475],"Emotion","Parent-Child Relations",[2460],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"intervention":1760,"totalTrials":132,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":100},[],{"trials":2490,"activeCount":100},[2491],{"nctId":1752,"briefTitle":1753,"status":120,"phases":2492,"primaryCompletion":1755,"start":1756,"enrollment":19,"conditions":2493,"interventions":2494},[88],[1758],[1760,1761,129,1762,1763],{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":1761,"totalTrials":132,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[2509],{"nctId":1752,"briefTitle":1753,"status":120,"phases":2510,"primaryCompletion":1755,"start":1756,"enrollment":19,"conditions":2511,"interventions":2512},[88],[1758],[1760,1761,129,1762,1763],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[],{"intervention":1762,"totalTrials":132,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2524,"activeCount":100},[],{"trials":2526,"activeCount":100},[2527],{"nctId":1752,"briefTitle":1753,"status":120,"phases":2528,"primaryCompletion":1755,"start":1756,"enrollment":19,"conditions":2529,"interventions":2530},[88],[1758],[1760,1761,129,1762,1763],{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"intervention":1763,"totalTrials":132,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2549,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2542,"activeCount":100},[],{"trials":2544,"activeCount":100},[2545],{"nctId":1752,"briefTitle":1753,"status":120,"phases":2546,"primaryCompletion":1755,"start":1756,"enrollment":19,"conditions":2547,"interventions":2548},[88],[1758],[1760,1761,129,1762,1763],{"trials":2550,"activeCount":100},[],{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":100},[],{"intervention":2558,"totalTrials":132,"cells":2559},"Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy",{"EARLY_PHASE1":2560,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2561,"activeCount":100},[2562],{"nctId":2563,"briefTitle":2564,"status":187,"phases":2565,"primaryCompletion":2566,"completion":2566,"start":2567,"enrollment":9,"conditions":2568,"interventions":2570},"NCT02369432","Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis",[87],"2017-10-03","2015-02-20",[2569],"Atopic Dermatitis",[2558],{"trials":2572,"activeCount":100},[],{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[],{"intervention":2582,"totalTrials":132,"cells":2583},"BRCA mutation",{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2585,"activeCount":100},[],{"trials":2587,"activeCount":100},[],{"trials":2589,"activeCount":100},[],{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[2596],{"nctId":2597,"briefTitle":2598,"status":120,"phases":2599,"primaryCompletion":2600,"completion":2600,"start":2601,"enrollment":2602,"conditions":2603,"interventions":2606},"NCT04012229","IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)",[],"2018-06-21","2017-07-28",2295,[15,2604,2605],"BRCA1 Mutation","BRCA2 Mutation",[2582],{"intervention":2608,"totalTrials":132,"cells":2609},"DCF regimen",{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2611,"activeCount":100},[],{"trials":2613,"activeCount":100},[],{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[2622],{"nctId":2623,"briefTitle":2624,"status":120,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":1210,"conditions":2629,"interventions":2632},"NCT01845779","Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal",[92],"2019-07","2019-12-31","2012-09",[2630,2631],"Metastatic Anal Canal Cancer","Human Papillomavirus",[2608],{"intervention":2634,"totalTrials":132,"cells":2635},"Identification of ABCB1 polymorphisms coding for P-gp",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2646},{"trials":2637,"activeCount":100},[],{"trials":2639,"activeCount":100},[],{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[2648],{"nctId":2649,"briefTitle":2650,"status":120,"phases":2651,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2654,"conditions":2655,"interventions":2659},"NCT02103101","Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events",[92],"2017-10-31","2014-11-13",68,[2656,2657,2658],"Anticoagulants","Thromboembolism","Hemorrhage",[2634],{"intervention":2661,"totalTrials":132,"cells":2662},"Benzimidazole",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675],{"nctId":2676,"briefTitle":2677,"status":120,"phases":2678,"primaryCompletion":2679,"completion":2679,"start":1388,"enrollment":1468,"conditions":2680,"interventions":2682},"NCT02876146","Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole",[92],"2021-08",[2681],"Alveolar Echinococcosis",[2661],{"intervention":2684,"totalTrials":132,"cells":2685},"urine analysis",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2694,"NA":2696},{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[2698],{"nctId":2699,"briefTitle":2700,"status":187,"phases":2701,"primaryCompletion":680,"completion":680,"start":2702,"enrollment":11,"conditions":2703,"interventions":2704},"NCT02856477","Pharmacogenetic and Antidepressant Treatment in Elderly",[92],"2007-11",[18],[2684],{"intervention":2706,"totalTrials":132,"cells":2707},"Taxane",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2716,"NA":2718},{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[2720],{"nctId":2721,"briefTitle":2722,"status":120,"phases":2723,"primaryCompletion":2724,"completion":2724,"start":2725,"enrollment":2726,"conditions":2727,"interventions":2731},"NCT04920747","Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients",[],"2021-05-31","2021-04-01",65,[2728,127,2729,2730],"HER2-positive Gastric Cancer","Docetaxel","Trastuzumab",[2706],{"intervention":2733,"totalTrials":132,"cells":2734},"Levobupivacaine Hydrochloride 2.5 MG\u002FML",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":100},[2747],{"nctId":2748,"briefTitle":2749,"status":120,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":1200,"conditions":2753,"interventions":2757},"NCT04969133","TAP Block Versus Local Anesthesia Wound Infiltration for Postoperative Pain Relief After Appendicectomy in Children",[92],"2024-01-31","2021-07-30",[2754,2755,2756],"Appendicitis Acute","Pediatrics","Analgesia",[2733],{"intervention":2759,"totalTrials":132,"cells":2760},"Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[2773],{"nctId":2774,"briefTitle":2775,"status":120,"phases":2776,"primaryCompletion":1986,"completion":1986,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2781},"NCT02859584","ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS",[92],"2011-08",111,[2780],"Acute Hepatitis",[2759],{"intervention":2783,"totalTrials":132,"cells":2784},"Dinoprostone 10mg",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"trials":2796,"activeCount":100},[2797],{"nctId":2798,"briefTitle":2799,"status":120,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":2803,"conditions":2804,"interventions":2807},"NCT04299854","Modality of Induction of Labor in Obese Women at Term (MODOBAT)",[],"2020-12-12","2020-06-11",77,[2805,2806],"Induction of Labor Affected Fetus \u002F Newborn","Obese",[2783],{"intervention":2809,"totalTrials":132,"cells":2810},"Anti PD1\u002FPDL1 treatment",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2821},{"trials":2812,"activeCount":100},[],{"trials":2814,"activeCount":100},[],{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[2823],{"nctId":2824,"briefTitle":2825,"status":120,"phases":2826,"primaryCompletion":2827,"completion":2828,"start":2829,"enrollment":2830,"conditions":2831,"interventions":2832},"NCT02840058","Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 \u002F PDL1",[92],"2024-07-23","2025-07-15","2016-08-31",295,[24],[2809],{"intervention":2834,"totalTrials":132,"cells":2835},"anti-TNF antibody administration",{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2837,"activeCount":100},[],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[2848],{"nctId":2849,"briefTitle":2850,"status":212,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2858},"NCT05244109","Biomedicines and Bacterial Translocation in Spondyloarthritis",[92],"2025-02","2025-05","2022-02-07",90,[2857],"Axial Spondyloarthritis",[2834,2859],"anti-IL-17 antibody administration",{"intervention":2859,"totalTrials":132,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2863,"activeCount":100},[],{"trials":2865,"activeCount":100},[],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[2874],{"nctId":2849,"briefTitle":2850,"status":212,"phases":2875,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2876,"interventions":2877},[92],[2857],[2834,2859],{"intervention":2879,"totalTrials":132,"cells":2880},"skin flakes collection",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2887,"PHASE4":2889,"NA":2891},{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[2893],{"nctId":2894,"briefTitle":2895,"status":187,"phases":2896,"primaryCompletion":2897,"completion":1256,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2902},"NCT02861404","Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment",[],"2014-10","2010-04",406,[2901],"Plantar Warts",[2879],{"intervention":2904,"totalTrials":132,"cells":2905},"ESBL-producing enterobacteriaceae carriage",{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[],{"trials":2915,"activeCount":100},[],{"trials":2917,"activeCount":100},[2918],{"nctId":2919,"briefTitle":2920,"status":120,"phases":2921,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":1441,"conditions":2925,"interventions":2928},"NCT03477084","Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities",[],"2019-07-01","2020-02-29","2017-03-01",[2926,2927],"Resistance Bacterial","Enterobacteriaceae Infections",[2904],{"intervention":2930,"totalTrials":132,"cells":2931},"blood taking",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2933,"activeCount":100},[],{"trials":2935,"activeCount":100},[],{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[2944],{"nctId":2945,"briefTitle":2946,"status":212,"phases":2947,"primaryCompletion":2948,"completion":2948,"start":2949,"enrollment":2950,"conditions":2951,"interventions":2953},"NCT02919709","Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells",[92],"2018-11","2013-11",40,[2952],"Thoracic or Abdominal Aortic Aneurysm With no Indication for Surgical Treatment",[2930],{"intervention":2955,"totalTrials":132,"cells":2956},"N2-L-Alanyl-L-Glutamine",{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[2969],{"nctId":2970,"briefTitle":2971,"status":120,"phases":2972,"primaryCompletion":2973,"completion":2974,"start":655,"enrollment":2975,"conditions":2976,"interventions":2980},"NCT03967795","Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients",[92],"2023-03-27","2023-04-24",73,[2977,2978,2979],"Enteral Nutrition","Intensive Care Unit","Biomarkers",[2955],{"intervention":2982,"totalTrials":132,"cells":2983},"Actilyse",{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2988,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[2996],{"nctId":2997,"briefTitle":2998,"status":120,"phases":2999,"primaryCompletion":3000,"completion":3001,"start":3002,"enrollment":3003,"conditions":3004,"interventions":3006},"NCT03451903","Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?",[],"2016-12-31","2018-02-01","2015-01-01",106,[3005],"Acute Stroke",[2982],{"intervention":738,"totalTrials":132,"cells":3008},{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[3021],{"nctId":729,"briefTitle":730,"status":212,"phases":3022,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":3023,"interventions":3024},[92],[736],[738,684]]